180 Life Sciences’ (ATNF) Sell (E+) Rating Reaffirmed at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a research report report published on Friday morning,Weiss Ratings reports.

180 Life Sciences Price Performance

180 Life Sciences stock opened at $1.18 on Friday. 180 Life Sciences has a 52 week low of $1.10 and a 52 week high of $17.75. The stock has a fifty day moving average of $1.45 and a 200-day moving average of $2.07.

Hedge Funds Weigh In On 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Rathbones Group PLC purchased a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned approximately 2.20% of 180 Life Sciences as of its most recent filing with the SEC. 4.07% of the stock is currently owned by institutional investors and hedge funds.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.